Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.36 EUR0.00 %20.10, 17.25
5,659 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Short Selling
Investor views
Compare
0.00 %
-11.69 %
-17.87 %
-45.92 %
-63.93 %
-62.84 %
-45.82 %
-86.99 %
-70.31 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
29.23M EUR
Turnover
23.65K EUR
P/E (adj.) (26e)
-10.74
EV/EBIT (adj.) (26e)
-7.44
P/B (26e)
1.37
EV/S (26e)
1.38
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
17.08.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Here’s another example of the kind of reports popping in from the agent every other day… rural + DR has quite some buzz going on. Optomed / Aurora AEYE – US Tracking 10/18/2026 Virginia: Two new DR funding decisions, totaling $566,000 This is a clear new finding strengthening the...
10/18/2026, 7:10 AM
by Puutaheinää
39
Apparently, West Virginia is also using a $2M pot of RHTP money for screening. This was announced on October 14. For this year, decisions to use RHTP money must be made by October 30, 2026. This program is for the years 2026–2030, with a $10B pot allocated for each year. governor...
10/18/2026, 2:05 PM
by j.sälli
23
Now these licenses are starting to roll in. Last week was the first foreign one, and now Hippos ATG. Shouldn’t some of these start trickling down to Ubetec? sttinfo.fi Hippos ATG sai rahapelitoimiluvan: Pohjoismaiden suurin vedonlyöntiyritys ATG... Ruotsalaisen ATG:n ja Suomen Hippos...
yesterday
by Mr. Stock
16
Interesting news from the US. So the regulatory bar is not being lowered, even though there is strong political will to increase the use of AI. As the agency faces backlogs and resource constraints, players that already hold FDA clearances for autonomous imaging and have solutions...
yesterday
by Mr. Stock
10
Eyenuk’s work is being valued quite nicely… hopefully, that will also reflect in the valuation of AEYE Health and perhaps even Optomed? LinkedIn #healthtech #aiinhealthcare #diabeticretinopathy #retinalimaging #milestone... We're honored to share that Eyenuk has been named to TIME...
yesterday
by Mr. Stock
9
As long as the financing risk remains even theoretical, the stock price will just drift sideways. As soon as that risk disappears after 2–3 quarters of solid track record, it will take off like a rocket. All that’s needed here is patience—it really is that simple.
10/17/2026, 1:38 PM
by marmot76
9
Here is a list of the currently FDA-cleared camera + AI combinations for retinopathy. Aeye is definitely still the strongest of these; offering both a tabletop camera and a handheld. UMass, for example, took both, and surely many other players will do the same. Each unit gets the...
10/18/2026, 4:19 PM
by j.sälli
7
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.11
2026

Interim report Q3'26

18.2
2027

Annual report '26

4.5
2027

Interim report Q1'27

Regulatory press release07.10.2026, 13.00

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release28.09.2026, 15.17

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.12

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.07

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.01

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release25.09.2026, 14.30

Optomed Oyj: Optomed's Board of Directors has resolved to establish a new stock option plan

Optomed
Optomeds dattercelskab Ubetec har vundet Veikkauses udbud
Analyst Comment07.09.2026, 06.55 by
Juha Kinnunen

Optomeds dattercelskab Ubetec har vundet Veikkauses udbud

Veikkaus' kontraktsejr på 0,9 MEUR styrker datterselskabet Ubetecin position på det åbne finske spillegældsmarked.

Optomed
Regulatory press release04.09.2026, 14.00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed